Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HCAR3 | P49019 | 4/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6645913 | 0.84 | MAPT (0.53) | RAB9AMAPTALDH1A1HCAR3KMT2A | |
| SCHEMBL7238262 | 0.83 | HCAR3 (0.44) | CYP1A2CLK4CYP3A4ALOX15HSD17B10 | |
| SCHEMBL13763543 | 0.81 | HCAR3 (0.47) | CYP1A2CLK4CYP3A4ALOX15HSD17B10 | |
| SCHEMBL16609596 | 0.79 | RAB9A (0.51) | RAB9AMAPTALDH1A1HCAR3KMT2A | |
| SCHEMBL25056983 | 0.79 | PRKAB2 (0.60) | RAB9ACYP1A2CLK4CYP3A4HSD17B10 | |
| SCHEMBL7233175 | 0.78 | GAA (0.65) | RAB9AMAPTCYP1A2ALDH1A1KMT2A | |
| SCHEMBL12830407 | 0.78 | MAPT (0.47) | RAB9AMAPTALDH1A1HCAR3KMT2A | |
| SCHEMBL12832042 | 0.78 | RAB9A (0.52) | RAB9AMAPTCLK4HSD17B10ALDH1A1 | |
| SCHEMBL1695279 | 0.76 | RAB9A (0.59) | RAB9AMAPTHSD17B10ALDH1A1KMT2A | |
| SCHEMBL10293613 | 0.75 | HCAR3 (0.57) | RAB9AMAPTALDH1A1HCAR3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153628-B2 | Pyrazolyl substituted xanthines | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-04-10 | — | — | US | disclosed |
| US-8153628-B2 | Pyrazolyl substituted xanthines | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-04-10 | — | — | US | disclosed |
| EP-2295434-A2 | Substituted 8-heteroaryl xanthines | Adenosine Therapeutics, LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | PGXHEALTH, LLC (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | PGXHEALTH, LLC (US) | 2010-10-28 | — | — | US | disclosed |
| US-7732455-B2 | Substituted 8-heteroaryl xanthines | PGX HEALTH, LLC (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732455-B2 | Substituted 8-heteroaryl xanthines | PGX HEALTH, LLC (US) | 2010-06-08 | — | — | US | disclosed |
| US-20100120765-A1 | PYRAZOLYL SUBSTITUTED XANTHINES | PGXHEALTH, LLC (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120765-A1 | PYRAZOLYL SUBSTITUTED XANTHINES | PGXHEALTH, LLC (US) | 2010-05-13 | — | — | US | disclosed |
| US-7618962-B2 | Pyrazolyl substituted xanthines | PGX HEALTH, LLC (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ALLERGAN SALES, LLC | 2008-08-21 | — | — | US | disclosed |
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ALLERGAN SALES, LLC | 2008-08-21 | — | — | US | disclosed |
| US-7342006-B2 | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342006-B2 | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120765-A1 | PYRAZOLYL SUBSTITUTED XANTHINES | ADORA2B, ADORA2A, ADORA3 | RAB9A 2666/4885MAPT 4515/4885CYP1A2 276/4885 |
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ADORA2B, ADORA2A, ADORA3 | RAB9A 2151/4885MAPT 4665/4885CYP1A2 203/4885 |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | ADORA2B, ADORA2A, ADORA3 | RAB9A 2151/4885MAPT 4665/4885CYP1A2 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.